Toll-Like Receptors As Potential Therapeutic Targets for Multiple Diseases

Total Page:16

File Type:pdf, Size:1020Kb

Toll-Like Receptors As Potential Therapeutic Targets for Multiple Diseases REVIEWS TOLL-LIKE RECEPTORS AS POTENTIAL THERAPEUTIC TARGETS FOR MULTIPLE DISEASES Claudia Zuany-Amorim, John Hastewell and Christoph Walker The family of Toll-like receptors (TLRs) is receiving considerable attention as potential regulators and controllers of the immune response through their ability to recognize pathogen-associated molecular patterns. The discovery that endogenous ligands, as well as microbial components, are recognized by TLRs, and that small-molecular-mass synthetic compounds activate TLRs, raised interest in these receptors as potential targets for the development of new therapies for multiple diseases. In this review, we discuss the current and future use of TLR agonists or antagonists in chronic inflammatory diseases and highlight potential problems that are associated with such approaches. 2 INNATE IMMUNITY The immune system has been divided traditionally into PAMPs . The first report of a mammalian TLR and its The early response of a host to an INNATE and ADAPTIVE component, each of which has involvement in host defence — TLR-4 as a receptor for infections by pathogens, such as different roles and functions in defending the organism LIPOPOLYSACCHARIDE (LPS)3 — was followed rapidly by the bacteria and viruses, before the against foreign agents, such as bacteria or viruses. The discovery that the human genome contains several antigen-specific, adaptive innate immune system has developed a series of con- TLRs — ten have been found so far, TLR-1–TLR-10. immune response is induced. served receptors, known as pattern-recognition recep- Members of the TLR family share characteristic extra- ADAPTIVE IMMUNITY tors (PRRs), that recognize specific pathogen-associated cellular and cytoplasmic domains. Their extracellular Also known as acquired molecular patterns (PAMPs), thereby allowing the innate domains include several leucine-rich repeats (LRRs), immunity. Host defence that is immune system to distinguish self-molecules from whereas the cytoplasmic domain is similar to the cyto- mediated by B and T cells after exposure to antigen and which pathogen-associated non-self structures and initiate plasmic portion of the interleukin-1 receptor (IL-1R), 1 shows specificity, memory and the host defence response . Recognition of PAMPs by which is commonly known as the Toll/IL-1R homolo- self/non-self recognition. PRRs results in the activation of signalling events that gous region (TIR domain)4. Consistent with their func- induce the expression of effector molecules, such as tion as PRRs, TLRs are expressed mainly in the cell cytokines, chemokines and co-stimulatory molecules, types that are involved in the first line of defence, such which subsequently control the activation of an antigen- as DENDRITIC CELLS, MACROPHAGES, NEUTROPHILS, mucosal specific adaptive immune response. An important epithelial cells and dermal endothelial cells5. Distinct advance in our understanding of early events in micro- subsets of dendritic cells and dendritic-cell precursors bial recognition and the subsequent development of express different subsets of TLRs that enable them to Novartis Horsham immune responses has been the identification of Toll- induce specific patterns of immune response to differ- Research Centre, Novartis Pharmaceutical like receptors (TLRs) as key PRRs of the innate ent pathogens. For example, plasmacytoid dendritic Ltd, Wimblehurst Road, immune system1. cells strongly express TLR-9, whereas myeloid dendritic Horsham, West Sussex The gene that encodes the Toll protein was shown to cells do not. Instead, they express other TLRs, including RH12 5AB, UK. be involved in embryonic development in Drosophila, TLR-4, which cause them to be activated by a different Correspondence to C.W. and was identified subsequently as being an essential set of PAMPs, including LPS6. Activation of dendritic e-mail: christoph.walker@ pharma.novartis.com molecule for driving the immune response. TLRs are cells by stimulation of TLRs results in the production of doi:10.1038/nrd914 mammalian homologues of this protein that can detect cytokines, such as IL-12, that induce T-helper type 1 NATURE REVIEWS | DRUG DISCOVERY VOLUME 1 | OCTOBER 2002 | 797 © 2002 Nature Publishing Group REVIEWS Table 1 | TLR-family members and exogenous and endogenous ligands TLR-family member Exogenous ligands Endogenous ligands TLR-1 (can associate with TLR-2) Mycobacterial lipoprotein, triacylated Unknown lipopeptides TLR-2 LPS, yeast-particle zymosan, peptidoglycan HSP60, surfactant protein-A (can associate with TLR-1 or TLR-6) (bacteria), lipoproteins (bacteria and mycoplasmas), GPI anchor from Trypanosoma cruzi TLR-3 Poly(I:C) (viral dsRNA) Unknown TLR-4 LPS, respiratory syncytial virus HSP60, HSP70, saturated LIPOPOLYSACCHARIDE fatty acids, unsaturated fatty (LPS). A lipopolysaccharide acids, hyaluronic-acid comprises three regions: fragment, surfactant protein-A a branched core oligosaccharide, TLR-5 Flagellin Unknown linked to a lipid component and an O-linked oligosaccharide. TLR-6 (can associate with TLR-2) Mycoplasma lipoproteins, lipoteichoic acid, Unknown The exact composition differs peptidoglycan (bacteria) between Gram-negative TLR-7 Unknown; synthetic compounds, such Unknown bacteria. LPS induces an acute as resiquimod or imiquimod, activate inflammatory reaction both the receptor in vitro and in vivo. TLR-8 Unknown; synthetic compounds, such as Unknown resiquimod or imiquimod, activate the DENDRITIC CELL receptor A bone-marrow-derived leukocyte that is specialized TLR-9 CpG DNA dsDNA for the uptake, transport, TLR-10 Unknown Unknown processing and presentation CpG, cytosine–guanine repeat; ds, double stranded; GPI, glycosyl phosphatidylinositol; HSP, heat-shock protein; LPS, lipopolysaccharide; of antigens to T cells. Poly(I:C), poly(inosine: cytidylic) acid; TLR, Toll-like receptor. MACROPHAGE A large, myeloid cell derived (T 1) CELLS from a monocyte in the H , which tends to direct the adaptive immune Tlr-2-deficient mice have a normal inflammatory 6 circulation that functions in response to differentiate towards a TH1 phenotype .The response to LPS, but macrophages from these animals phagocytosis, antigen processing identification of TLRs as PRRs that are involved in con- are less responsive to Gram-positive bacterial cell walls and presentation, secretion of trolling dendritic-cell activation led to substantial interest and PEPTIDOGLYCAN. Indeed, TLR-2 recognizes LPS from cytokines and antibody- in these receptors as possible regulators of adaptive Porphyromonas gingivitis9 and Leptospira interrogans10, dependent, cell-mediated cytotoxicity. immune responses and, by inducing a specific cytokine which differs in structure from the LPS of Gram-negative environment, their involvement in the pathogenesis of bacteria. These results are evidence of TLR selectivity in NEUTROPHIL several chronic inflammatory diseases. Therefore, we PAMP recognition, although other TLRs can recognize A circulating granulocyte that focus our discussion on the emerging role of TLRs in the the same components of both Gram-negative and can phagocytose pathogens, such as bacteria, and release pathogenesis of inflammatory diseases and how agonists Gram-positive bacteria. Indeed, flagellin, the principal proteolytic enzymes. or antagonists of these receptors might be used to treat element of bacteria flagella, is a highly virulent molecule various pathological conditions. We describe the basic that is recognized by TLR-5 (REF.11), whereas TLR-9 is T 1 CELL H mechanism of an allergic inflammatory response as an required for the inflammatory response that is triggered A terminally differentiated example to show how targeting TLRs might offer promis- by hypomethylated bacterial DNA12. TLRs also trigger subclass of T-helper cell that secretes a restricted repertoire ing new therapeutic benefits. In addition, the current and an innate immune response to viruses that produce of cytokines, including IL-2 future use of TLR agonists and antagonists in other double-stranded RNA, and a reduced response to the and IFN-γ. chronic inflammatory diseases, and the activation of dsRNA analogue polyinosine–polycytidylic acid was TLRs by exogenous or endogenous ligands are discussed. observed in Tlr-3-deficient mice13. Recently, Takeuchi GRAM-NEGATIVE BACTERIA 14 Bacteria that do not retain a et al. showed that TLR-1 is involved in the recognition basic blue dye during the Gram TLRs: members and ligands of mycobacterial lipoprotein and triacylated lipopetides. stain procedure. Their cell walls Several reviews describe elegantly the known members In addition, TLRs can form multimeric complexes are thin, consisting of a layer of of the TLR family, their ligands and the signalling path- (homodimers or heterodimers) to increase the spec- lipopolysaccharide outside of ways that are induced by stimulation of the receptors4–6. trum of molecules that they recognize. For example, the a peptidoglycan layer. Therefore, we summarize only briefly the current know- cytoplasmic domain of TLR-2 can form functional pairs GRAM-POSITIVE BACTERIA ledge, focusing on the most important information that with TLR-6 and TLR-1, leading to signal transduction Bacteria that retain a basic blue is required to understand the function of TLRs (TABLE 1). and cytokine expression after ligand activation4. dye during the Gram-stain Different TLRs have been shown to be crucial for the procedure. Their cell wall is thicker than that of Gram- selective recognition of specific PAMPs that are common TLR signal transduction negative
Recommended publications
  • Newer Trends in the Management of Genital Herpes
    Review NNewerewer trendstrends inin thethe mmanagementanagement ofof genitalgenital herpesherpes Article AAmiyamiya KKumarumar NNath,ath, DDevinderevinder MohanMohan ThappaThappa Department of Dermatology ABSTRACT and STD, Jawaharlal Institute of Postgraduate Medical Management of genital herpes is complex. Apart from using the standard antivirals, an Education and Research (JIPMER), Pondicherry - 605 ideal management protocol also needs to address various aspects of the disease, including 006, India the psychological morbidity. Oral acyclovir, valacyclovir or famciclovir are recommended for routine use. Long-term suppressive therapy is effective in reducing the number of AAddressddress forfor ccorrespondence:orrespondence: recurrences and the risk of transmission to others. Severe or disseminated disease may Dr. Devinder Mohan Thappa, require intravenous therapy. Resistant cases are managed with foscarnet or cidofovir. Genital Department of Dermatology herpes in human immunodeÞ ciency virus-infected individuals usually needs a longer duration and STD, JIPMER, of antiviral therapy along with continuation of highly active anti retroviral therapy (HAART). Pondicherry - 605 006, India. E-mail: [email protected] Genital herpes in late pregnancy increases the risk of neonatal herpes. Antiviral therapy and/or cesarean delivery are indicated depending on the clinical circumstance. Acyclovir appears to be safe in pregnancy. But, there is limited data regarding the use of valacyclovir and famciclovir in pregnancy. Neonatal herpes requires a higher dose of acyclovir given intravenously for a longer duration. Management of the sex partner, counseling and prevention advice are equally important in appropriate management of genital herpes. Vaccines till date have been marginally effective. Helicase–primase inhibitors, needle-free mucosal vaccine and a new microbicide product named VivaGel may become promising treatment options in the future.
    [Show full text]
  • United States Patent (10) Patent No.: US 7,935,351 B2 Klinman Et Al
    US007935351B2 (12) United States Patent (10) Patent No.: US 7,935,351 B2 Klinman et al. (45) Date of Patent: *May 3, 2011 (54) USE OF CPG OLIGODEOXYNUCLEOTIDES 35. A 3. 2. RS:udolph s et alal. TO INDUCE ANGOGENESIS 5,288,509 A 2f1994 Potman et al. 5.488,039 A 1, 1996 M tal. (75) Inventors: Dennis M. Klinman, Potomac, MD 5.492.899 A 2, 1996 NE al. (US); Mei Zheng, Augusta, GA (US); 5,585,479 A 12/1996 Hoke et al. Barry T. Rouse, Knoxville, TN (US) 5,602,1095,591,721 A 2/19971/1997 MasorAgrawal et etal. al. 5,612,060 A 3, 1997 A1 d (73) Assignees: The United States of America as 5,614,191 A 3, 1997 al represented by the Department of 5,650,156 A 7/1997 Grinstaffet al. Health and Human Services, 5,663,153 A 9, 1997 Hutcerson et al. Washington, DC (US); University of 3. A RE SEE, Tennessee Research Foundation, 5,700,590 A 12/1997 Masoretal Knoxville, TN (US) 5,712.256 A 1/1998 Kulkarni et al. 5,723,335 A 3, 1998 Hutcerson et al. (*) Notice: Subject to any disclaimer, the term of this 3. 2. A 38. El cal patent is extended or adjusted under 35 5.840,705 A 11/1998 Tsukuda U.S.C. 154(b) by 761 days. 5,849,719 A 12, 1998 Carson et al. This patent is Subject to a terminal dis- 33: A 23: SEE claimer. 5,922,766 A 7/1999 Acosta et al.
    [Show full text]
  • The Effects of Atopy and Asthma on in Vivo Human Nasal Responses to Toll
    The effects of atopy and asthma on in vivo human nasal responses to Toll-like receptor agonists Dr Akhilesh Jha A thesis submitted for the degree of Doctor of Philosophy (PhD) Centre for Respiratory Infection National Heart and Lung Institute (NHLI), St Mary’s Campus Imperial College London, Norfolk Place, London W2 1PG July 2018 Abstract Acute respiratory viral infections cause significant morbidity and mortality, especially in vulnerable individuals, and it is important to study viral pathogenesis and the host immune response in humans. Toll-like receptors (TLRs) play a critical role in the detection of viral nucleic acids, and airway TLR receptors respond to nucleic acid patterns in the RNA viruses that cause respiratory infections. However, a reliable method of measuring mucosal innate immune responses to viral infections is lacking. TLR3 agonists (poly(I:C) and poly-ICLC) and the combined TLR7/8 agonist (resiquimod, R848) are synthetic analogues of double stranded RNA (dsRNA) and single stranded RNA (ssRNA) respectively. Nasal challenge with these TLR agonists was carried out, and serial sampling using nasosorption and nasal curettage was performed. Mucosal immune responses were measured and the effect of different host factors (e.g. asthma) on these responses was studied. Poly(I:C) and poly-ICLC were well tolerated but failed to induce significant and reliable nasal mucosal innate immune responses. R848 at a higher dose (10 µg/100 µL per nostril) induced significant mucosal interferon and cytokine responses but caused mild to moderate flu-like symptoms in three out of nine volunteers. A lower dose of R848 (0.02 µg/kg/100 µL, mean dose 1.5 µg/100 µL) was subsequently utilised in three groups of volunteers: healthy non-atopic (n=12), allergic rhinitis (n=12) and allergic asthma (n=11).
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Bioinformatics Review of the Role of HSV-1 in Alzheimer's Disease
    Advances in Alzheimer’s Disease, 2020, 9, 57-75 https://www.scirp.org/journal/aad ISSN Online: 2169-2467 ISSN Print: 2169-2459 Bioinformatics Review of the Role of HSV-1 in Alzheimer’s Disease Brian T. Reiss1, Meade C. Eggleston1, Arah C. Godbole1, Julia A. Marut1, Cecelia M. McCann1, Jessica A. Cottrell1, Tinchun Chu1, Sulie L. Chang1,2* 1Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA 2Institute of Neuroimmune Pharmacology, Seton Hall University, South Orange, NJ, USA How to cite this paper: Reiss, B.T., Eg- Abstract gleston, M.C., Godbole, A.C., Marut, J.A., McCann, C.M., Cottrell, J.A., Chu, T.C. and Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the Chang, S.L. (2020) Bioinformatics Review progressive loss of cognitive functions in affected individuals. Brain tissue of the Role of HSV-1 in Alzheimer’s Dis- pathology is associated with the formation of senile plaques which result from ease. Advances in Alzheimer’s Disease, 9, 57-75. the over-production of amyloid β (Aβ), due to the cleavage of a membrane https://doi.org/10.4236/aad.2020.93005 bound glycoprotein. It is unclear what causes AD and its associated patholo- gies, but age and genetic predisposition play an import role in the likelihood Received: June 11, 2020 Accepted: September 6, 2020 of disease development. Studies have shown that the reactivation of latent Published: September 9, 2020 herpes simplex virus 1 (HSV-1) infection can lead to the neuropathy of acute herpes simplex encephalitis (HSE), which causes similar symptoms to AD.
    [Show full text]
  • Activation of Anti-Hepatitis C Virus Responses Via Toll-Like Receptor 7
    Activation of anti-hepatitis C virus responses via Toll-like receptor 7 Jongdae Lee*, Christina C. N. Wu*†, Ki Jeong Lee‡, Tsung-Hsien Chuang§, Kyoko Katakura*, Yu-Tsueng Liu*†, Michael Chan†, Rommel Tawatao†, Michelle Chung*, Carol Shen*, Howard B. Cottam†, Michael M. C. Lai‡, Eyal Raz*, and Dennis A. Carson†¶ *Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0663; †Moores Cancer Center, University of California at San Diego Medical Center, La Jolla, CA 92093-0820; ‡Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033; and §Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037 Contributed by Dennis A. Carson, December 15, 2005 IFN-␣ is used to suppress the replication of hepatitis C virus (HCV) in HCV replicon cells. The IRFs can both foster type I IFN in chronically infected patients with partial success. Here we production (18) and enhance the antiviral activity of these present evidence showing that a ligand of Toll-like receptor 7 cytokines (19). Thus, pharmacologic agents that activate IRFs in (TLR7) can induce anti-HCV immunity not only by IFN induction, but hepatocytes may exert direct anti-HCV effects, as well as po- also through an IFN-independent mechanism. Human hepatocyte tentiate IFN action. line Huh-7 carrying an HCV replicon expressed TLR7, and activation Pharmacologic inhibitors of the enzyme inosine monophos- of the receptor induced several antiviral genes including IFN phate dehydrogenase (IMPDH), including ribavirin and mizor- regulatory factor-7. Inhibitors of the enzyme inosine monophos- ibine, have been reported to have activity against RNA viruses phate dehydrogenase augmented both IFN-dependent and -inde- (18–20).
    [Show full text]
  • Annual Report 2016
    Annexes to the annual report of the European Medicines Agency 2016 Annex 1 – Members of the Management Board ............................................................... 2 Annex 2 - Members of the Committee for Medicinal Products for Human Use ...................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ........................ 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ................. 8 Annex 5 – Members of the Committee on Orphan Medicinal Products .............................. 10 Annex 6 – Members of the Committee on Herbal Medicinal Products ................................ 12 Annex 7 – Committee for Advanced Therapies .............................................................. 14 Annex 8 – Members of the Paediatric Committee .......................................................... 16 Annex 9 – Working parties and working groups ............................................................ 18 Annex 10 – CHMP opinions: initial evaluations and extensions of therapeutic indication ..... 24 Annex 10a – Guidelines and concept papers adopted by CHMP in 2016 ............................ 25 Annex 11 – CVMP opinions in 2016 on medicinal products for veterinary use .................... 33 Annex 11a – 2016 CVMP opinions on extensions of indication for medicinal products for veterinary use .......................................................................................................... 39 Annex 11b – Guidelines and concept papers adopted by CVMP in 2016 ...........................
    [Show full text]
  • Naive Alum | IMQ-Cpg
    US010485861B2 United States Patent (10 ) Patent No.: US 10,485,861 B2 Stary et al. (45 ) Date of Patent : Nov. 26 , 2019 (54 ) NANOPARTICLE -BASED COMPOSITIONS Related U.S. Application Data ( 71) Applicants : President and Fellows of Harvard (60 ) Provisional application No. 61/ 783,439 , filed on Mar. College , Cambridge , MA (US ) : 14 , 2013 . Massachusetts Institute of (51 ) Int. CI. Technology , Cambridge , MA (US ); The A61K 39/118 (2006.01 ) Brigham and Women's Hospital, Inc., A61K 45/06 ( 2006.01) Boston , MA (US ) (Continued ) (52 ) U.S. CI. (72 ) Inventors : Georg Stary, Brookline, MA (US ) ; CPC A61K 39/118 (2013.01 ) ; A61K 31/4745 Aleksandar Filip Radovic -Moreno , ( 2013.01 ) ; A61K 31/711 ( 2013.01) ; State College , PA (US ) ; Pamela A. (Continued ) Basto , Cambridge, MA (US ) ; Michael ( 58 ) Field of Classification Search N. Starnbach , Needham , MA (US ) ; CPC A61K 9/10 ; A61K 35/74 ; A61K 39/39 ; Robert S. Langer , Newton , MA (US ) ; A61K 39/522 ; A61K 39/55555 ; Omid C. Farokhzad , Waban , MA (US ) ; Ulrich Von Andrian , Chestnut (Continued ) Hill , MA (US ) ( 56 ) References Cited (73 ) Assignees: President and Fellows of Harvard U.S. PATENT DOCUMENTS College, Cambridge , MA (US ) ; Massachusetts Institute of 3,960,757 A 6/1976 Morishita et al . Technology , Cambridge, MA (US ) ; The 4,638,045 A 11/1987 Kohn et al . Brigham and Women's Hospital, Inc. , (Continued ) Boston , MA (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this WO WO1997028259 8/1997 patent is extended or adjusted under 35 WO WO1998016247 4/1998 U.S.C. 154 ( b ) by 0 days .
    [Show full text]
  • Breast Cancer Treatment with Imiquimod: Applying an Old Lotion to a New Disease
    Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-3138 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Breast cancer treatment with imiquimod: Applying an old lotion to a new disease Holbrook Kohrt, MD PhD Stanford University Cancer Institute Department of Medicine, Division of Oncology Stanford, CA 94305 Title: 79 characters Abstract: 49 words Text: 1200 words References: 12 references The author has no conflicts of interest. Running Title: Applying an old lotion to a new disease Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2012 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-3138 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Over the prior two decades, imiquimod, a toll-like receptor 7 agonist, has been applied to nearly fifty clinical settings. Due to its immunomodulatory role, the topical cream today for the first time, is being applied to cutaneous breast cancer in pre-clinical models and in a Phase 2 clinical trial. Manuscript In this issue of Clinical Cancer Research, two sets of authors from Demaria’s group, Dewan et al. (1) and Adams et al. (2) detail in companion papers the anti-tumor efficacy of imiquimod in first, a preclinical breast cancer model in combination with radiation (1), and second, a Phase 2, breast cancer clinical trial assessing safety and immunologic activity (2). Fifteen years after first approval by the Food and Drug Administration (FDA), imiquimod remains the only approved, active toll-like receptor (TLR) agonist (3).
    [Show full text]
  • Human Naive B Cells Cells by Cpg Oligodeoxynucleotide-Primed T+
    Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells This information is current as Wei Jiang, Michael M. Lederman, Clifford V. Harding and of September 27, 2021. Scott F. Sieg J Immunol 2011; 186:2080-2086; Prepublished online 14 January 2011; doi: 10.4049/jimmunol.1001869 http://www.jimmunol.org/content/186/4/2080 Downloaded from References This article cites 36 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/186/4/2080.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells Wei Jiang,*,† Michael M. Lederman,*,† Clifford V. Harding,†,‡ and Scott F. Sieg*,† Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8+ T cells.
    [Show full text]
  • Toll-Like Receptor 9 and 21 Have Different Ligand Recognition Profiles
    Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish Da-Wei Yeha,b,1, Yi-Ling Liua,1, Yin-Chiu Loc, Chiou-Hwa Yuhd, Guann-Yi Yuc, Jeng-Fan Loe, Yunping Luof, Rong Xiangg, and Tsung-Hsien Chuanga,h,2 aImmunology Research Center, National Health Research Institutes, Miaoli 35053, Taiwan; bInstitute of Molecular Medicine, National Tsing-Hua University, HsinChu 30013, Taiwan; cNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 35053, Taiwan; dInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli 35053, Taiwan; eInstitute of Oral Biology, National Yang-Ming University, Taipei 11221, Taiwan; fDepartment of Immunology, School of Basic Medicine, Peking Union Medical College, Beijing 100005, People’s Republic of China; gSchool of Medicine, University of Nankai, Tianjin 300071, People’s Republic of China; and hProgram in Environmental and Occupational Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan Edited by Ken J. Ishii, National Institute of Biomedical Innovation, Ibaraki, Japan, and accepted by the Editorial Board October 29, 2013 (received for review March 21, 2013) CpG-oligodeoxynucleotides (CpG-ODNs) are potent immune stim- containing a GTCGTT motif. In contrast, the GTCGTT motif uli currently under investigation as antimicrobial agents for containing CpG-ODN generates stronger immune responses in different species. Toll-like receptor (TLR) 9 and TLR21 are the humans and various domestic animals (8, 9). cellular receptors of CpG-ODN in mammals and chickens, respec- Toll-like receptors (TLRs) are pattern recognition recep- tively. The avian genomes lack TLR9, whereas mammalian tors that play crucial roles in the initiation of host defense genomes lack TLR21.
    [Show full text]
  • Time-Resolved Effect of Interferon-Alpha 2A on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes
    pharmaceutics Article Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes Dirk Theile , Lelia Wagner , Cindy Bay, Walter Emil Haefeli and Johanna Weiss * Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; [email protected] (D.T.); [email protected] (L.W.); [email protected] (C.B.); [email protected] (W.E.H.) * Correspondence: [email protected]; Tel.: +49-6221-5639402 Abstract: Interferon-alpha (IFN-α) is suggested to cause pharmacokinetic drug interactions by lowering expression of drug disposition genes through affecting the activities of nuclear factor kappa B (NF-kB) and pregnane X receptor (PXR). The time-resolved impact of IFN-α 2a (1000 U/mL; 5000 U/mL; 2 h to 30 h) on the activities of NF-kB and PXR and mRNA expression (5000 U/mL; 24 h, 48 h) of selected drug disposition genes and on cytochrome P450 (CYP3A4) activity in LS180 cells (5000 U/mL; 24 h, 48 h) was evaluated using luciferase-based reporter gene assays, reverse transcription polymerase chain reaction, and luminescence-based CYP3A4 activity assays. The cross- talk between NF-kB activation and PXR suppression was evaluated by NF-kB blockage (10 µM parthenolide). IFN-α 2a initially (2 h, 6 h) enhanced NF-kB activity 2-fold and suppressed PXR Citation: Theile, D.; Wagner, L.; activity by 30%. mRNA of CYP3A4 was halved, whereas UGT1A1 was increased (1.35-fold) after Bay, C.; Haefeli, W.E.; Weiss, J.
    [Show full text]